Search Results for “EU” – Page 37 – media

A Comprehensive Guide

Pharmaceutical businesses face a unique challenge: they must navigate a maze of strict industry standards when marketing their products, ensuring every step aligns with industry regulations and legal requirements. While these constraints can seem daunting, digital marketing holds vast potential for these enterprises, offering myriad channels and methods to craft compelling strategies that not only resonate with potential audiences but also remain compliant. Drugdu.com has summarized five digital marketing strategies specifically for the industry: 1.Gain Attention on Search Engines Using SEO Search Engine Optimization (SEO) is the cornerstone of any online digital marketing. It ensures your website or page appears in the search engine results, leading customers to you. As SEO can drive traffic to your website, it plays an indispensable role in pharmaceutical digital marketing. To stand out amongst numerous websites, optimization is key. How to achieve a good ranking in search engines? ① Optimize titles and tags ② Eye-catching ...
- Source: drugdu
- 355
- August 18, 2023
B2B Platforms Content Marketing Digital Marketing Pharmaceutical Companies Reputation Management SEO Social Media
【EXPERT Q&A】For pharmaceutical exports to the United States, after obtaining FDA certification, is there still a need for an import permit from the U.S.?

Drugdu.com expert’s response: To export pharmaceuticals to the United States, in addition to obtaining FDA certification, one must also comply with other U.S. import regulations. After receiving FDA approval, the drug also needs to adhere to the import regulations set by the U.S. Customs and Border Protection (CBP). Sometimes, this may involve obtaining additional import permits or certificates, but the specific requirements can vary based on the type of product and specific circumstances. Before shipping the drug to the U.S., ensure that you are familiar with and compliant with all relevant regulations. Collaborating with local import/export agents might be helpful as they are typically knowledgeable about these regulations and can provide specific guidance.
- Source: drugdu
- 210
- August 17, 2023
FDA approval import permit
Researchers publish early results with new interleukin-targeting antibody

An academic group has published preclinical results with a new antibody that has greater activity and fewer side effects than existing biological therapies for inflammatory conditions. This could translate into a clinical benefit for patients living with rheumatoid arthritis (RA), psoriasis, or inflammatory bowel disease (IBD). Researchers from the University of Birmingham in the UK and the University of Naples Federico II in Italy revealed promising results after designing an antibody that targets a 20-long amino acid sequence in interleukin-17 (IL-17) – a protein important in inflammatory pathways. According to the team, they demonstrated for the first time that this sequence activates the release of cyto-chemokines. The antibody, which has been called Ab-IPL-IL-17, targets this sequence in both IL-17A and IL-17F. In cell studies, it demonstrated an ability to reduce the production of cyto-chemokines and white blood cell migration to inflammation-primed tissue. When the researchers compared it to existing therapies ...
- Source: drugdu
- 229
- August 17, 2023
Regeneron to acquire Decibel Therapeutics in deal worth up to $213m

Regeneron Pharmaceuticals has entered into a definitive agreement to acquire hearing loss specialist Decibel Therapeutics in a deal worth as much as $213m. The transaction gives Regeneron access to investigational gene therapy, DB-OTO, which is designed to provide hearing to people with otoferlin-related hearing loss. The candidate is currently in phase 1/2 clinical development. Under the terms of the agreement, Regeneron will pay $4 per share of Decibel common stock, with an additional non-tradeable contingent value right (CVR) for $3.50 apiece, upon achievement of certain clinical development and regulatory milestones for DB-OTO. The deal gives Decibel a total equity value of about $109m, based on the amount payable at closing, though that valuation increases to $213m if the CVR milestones are met. The agreement builds on the existing gene therapy collaboration between Regeneron and Decibel aimed at developing three programmes targeting different forms of congenital, monogenic hearing loss. There are ...
- Source: drugdu
- 123
- August 14, 2023
【EXPERT Q&A】How to promote pharmaceutical intermediates?

Drugdu.com expert’s response: Promoting pharmaceutical intermediates essentially hinges on market positioning and the intended target audience. Here are some effective methods to promote pharmaceutical intermediates: 1.Participate in Professional Expos: This provides an excellent opportunity to meet potential clients and showcase your products. You can display product samples and engage in face-to-face business discussions. 2. Establish an Official Website: By setting up an official website, you can showcase your company’s capabilities, product details, and enhance your corporate image. 3. Online Marketing: For instance, post product information on industry-specific websites. Using Search Engine Optimization (SEO) and Search Engine Marketing (SEM) strategies can boost the online visibility of your products. 4. Cold-call Potential Customers: Take the initiative to reach out to companies that might be interested. This can be done via emails or phone calls. 5. Promote through Industry-specific Platforms: Drugdu.com is a dedicated platform for medical imports and exports. It caters to industry ...
- Source: drugdu
- 238
- August 11, 2023
pharmaceutical intermediates
“Visual-movement” neurons in the brain help individuals to stay focused on rewarding tasks

Trying to finish your homework while the big game is on TV? “Visual-movement” neurons in the front of your brain can help you stay focused, according to a new study from neuroscientists in the Perelman School of Medicine at the University of Pennsylvania. In the study, published recently in Neuron, the scientists sought to illuminate the neural mechanism that helps the brain decide whether to focus visual attention on a rewarding task or an alluring distraction. By analyzing neuron activity in animal models as they faced this kind of attentional conflict, the researchers discovered that a pattern of coordinated activity called “beta bursts” in a set of neurons in the lateral prefrontal cortex (LPFC)-;a section in the front of the brain responsible for motivation and rewards-;appears to have a major role in keeping attention task-focused, essentially by suppressing the influence of the distracting stimulus. Bijan Pesaran PhD (senior author, the ...
- Source: drugdu
- 126
- August 11, 2023
CS Pharmaceuticals snaps up AxeroVision to shore up ophthalmology portfolio

CS Pharmaceuticals (CSP) has acquired AxeroVision for an undisclosed fee, in a move that will involve a dry eye disease (DED) candidate being transferred over to the UK-based ocular therapeutics company. CSP, which is headquartered in London but develops and commercialises treatments for eye diseases in China, will continue developing AXR-270, a selective glucocorticoid receptor agonist. The drug has been in a phase of developmental dormancy. In August 2021, AxeroVision released positive Phase II results for the candidate in 129 patients with DED with meibomian gland dysfunction (MGD). In a statement announcing the 2021 results, AxeroVision – which spun out from GSK in 2016 – said it was planning to enrol around 800 patients in a Phase III trial comparing the eye cream with a vehicle, and a new drug application/marketed authorisation application filing expected in 2024. However, the company did not issue any further updates on the drug since ...
- Source: drugdu
- 169
- August 4, 2023
US DoD backs potential treatment for Fragile X-linked neurodegenerative disorder

The US Department of Defense (DoD) has awarded PureTech Health $11.4m to help target Fragile X-associated tremor/ataxia syndrome (FXTAS), a late-onset neurological condition that is difficult to diagnose and currently has no effective treatments. Based in Massachusetts, US, Puretech Health will use the funds to advance LYT-300 in a Phase II trial. LYT-300 is an oral prodrug of allopregnanolone, which is known to regulate mood via its positive allosteric modulation of gamma-aminobutyric-acid type A (GABAA) receptors. It is already approved by the US Food and Drug Administration (FDA) as an infusion treatment for postpartum depression. PureTech Health said administration limitations have previously restricted the wider use of the neurosteroid. Developed using the company’s Glyph platform that harnesses natural lipid absorption and transport processes, LYT-300 can be orally administered. FXTAS occurs in premutation carriers of Fragile X Syndrome. Estimates suggest that 30%-40% of male carriers, and 8%-16% of premutation carriers will ...
- Source: drugdu
- 101
- August 3, 2023
Neuraxpham gears up to market TG’s relapsing MS treatment Briumvi in Europe

TG Therapeutics has signed an ex-US commercialisation agreement with Neuraxpham Group to launch its multiple sclerosis treatment Briumvi (ublituximab) in Europe. Briumvi is an anti-CD20 monoclonal antibody that has been approved in the US and European Union (EU) for relapsing forms of multiple sclerosis (RMS). Following the agreement, Neuraxpharm will also seek approvals in the UK and Switzerland. As per the agreement, TG will receive a $140m upfront payment followed by an additional $12.5m after the launch of Briumvi in the first EU country. Additional milestone-based payments of up to $492.5m are based on certain launch and commercial milestones. The deal news came on the same day as the company’s Q2 financial results. Following both announcements, there was a 42.5% decline in TG’s stock price at market open today, compared to the market close yesterday. In the Q2 earnings, TG Therapeutics reported he a loss of $86.8m and $47.6m for ...
- Source: drugdu
- 198
- August 3, 2023
Merck’s Pneumococcal Shot Claims Back-to-Back Phase III Wins

By Tristan Manalac Pictured: Merck sign at its office in California/iStock, hapabapa Merck’s investigational pneumococcal vaccine V116 aced two Phase III trials, eliciting strong immune responses in both the Phase III STRIDE-3 and STRIDE-6 trials, the company announced Thursday. Without providing specific data, the drugmaker said that in STRIDE-3, V116 significantly outperformed the standard 20-valent pneumococcal conjugate vaccine at eliciting an immune response in adults who had not been immunized before. Meanwhile, STRIDE-6 showed that Merck’s investigational shot could prime immunity against all 21 targeted pneumococcal serotypes in adults aged 50 years and above who had been vaccinated at least a year prior. Both STRIDE-3 and STRIDE-6 also demonstrated that V116’s safety profile was comparable to the standard vaccine comparator used in these studies. “Despite the availability of current pneumococcal conjugate vaccines, many adults remain vulnerable to pneumococcal disease, especially those who are older,” Merck Chief Medical Officer Eliav Barr ...
- Source: drugdu
- 125
- August 1, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.